对埃克塞纳提德的急性药理动力学反应:药物诱导的胰岛素分泌量增加和葡萄糖的有效性
Simeon I Taylor1, May E Montasser1, Ashley H Yuen1
1Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Diabetes, obesity & metabolism
|June 1, 2023
概括
像exenatide这样的葡萄糖类-1受体激动剂通过增加胰岛素分泌和葡萄糖清除来改善葡萄糖控制. 个体反应各不相同,这凸显了在2型糖尿病治疗中需要进行药物基因组学研究的需要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 代谢研究研究 代谢研究
背景情况:
- 类似葡萄糖类-1受体激动剂 (GLP-1RA) 对2型糖尿病患者提供显著的益处,包括血糖控制,体重控制和心血管风险降低.
- 对GLP-1RA的个体反应有所不同,因此需要对影响药物疗效的遗传因素进行研究.
研究的目的:
- 为了研究exenatide对健康志愿者的葡萄糖代谢的药理动力学影响.
- 为了验证使用频繁采样的静脉注射葡萄糖耐受性测试 (FSIGT),对GLP-1RA的药基因组学研究进行最小模型分析.
主要方法:
- 一项随机交叉试点研究,涉及62名健康志愿者.
- 施用exenatide (5μg,皮下注射) 或盐水,然后进行FSIGT以评估胰岛素分泌和作用.
- 最小模型分析量化葡萄糖有效性 (Sg) 和胰岛素敏感性 (Si).
主要成果:
- 埃克塞纳提德显著增加了第一阶段胰岛素分泌 (1.9倍) 和葡萄糖消失率 (2.4倍).
- 埃克萨纳提德增加了32%的葡萄糖有效性 (Sg),但没有显著改变胰岛素敏感性 (Si).
- 埃克塞纳提德对胰岛素分泌的影响的个体间变化是葡萄糖失踪率变化的主要驱动因素.
结论:
- 使用最小模型分析的FSIGT是评估GLP-1 RA药理动力学的宝贵工具.
- 第一阶段胰岛素分泌率和葡萄糖消失率是评估GLP-1RA影响的关键定量终点.
- 这项研究为正在进行的关于塞马格卢提德作用的药物基因组学研究提供了基础.
相关概念视频
Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
220
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
220
Hormones Regulating Blood Glucose
3.6K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.6K


